Chest, Vol 89, 497-503, Copyright © 1986 by American College of Chest Physicians

ARTICLES

Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension

RJ Barst

To evaluate pulmonary vasoreactivity in children and young adults with primary pulmonary hypertension, we performed cardiac catheterizations on nine patients with primary pulmonary hypertension (nine months to 23 years old) and made hemodynamic measurements: before and after infusing prostacyclin, and before and after administering sublingual nifedipine. Based upon the response to prostacyclin, patients were divided into responders and nonresponders using the following criteria: 20 percent or greater decrease in mean pulmonary arterial pressure; an increase in cardiac index; and no change, or a decrease in the pulmonary vascular resistance to systemic vascular resistance ratio. By these criteria, five of the nine patients had a reactive pulmonary vascular bed and responded to prostacyclin administration. In addition, they all responded to nifedipine. The remaining four did not respond to either drug. There was a close correlation (r = 0.85, p less than 0.01) between the magnitude of the pulmonary vasodilator response to treatment with prostacyclin and nifedipine. There was also a significant inverse correlation between the age of the patient at the time of the study and the pulmonary vasodilator response to administration of prostacyclin (r = 0.91, p less than 0.01) and nifedipine (r = 0.82, p less than 0.01); ie, both drugs produced a greater fall in pulmonary arterial pressure in younger patients with primary pulmonary hypertension than in older ones.

This article has been cited by other articles:

				E. B. Rosenzweig, D. D. Ivy, A. Widlitz, A. Doran, L. R. Claussen, D. Yung, S. H. Abman, A. Morganti, N. Nguyen, and R. J. Barst Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., August 16, 2005; 46(4): 697 - 704. [Abstract] [Full Text] [PDF]

				T. Humpl, J. T. Reyes, H. Holtby, D. Stephens, and I. Adatia Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study Circulation, June 21, 2005; 111(24): 3274 - 3280. [Abstract] [Full Text] [PDF]

				M.C. Post, S. Janssens, F. Van de Werf, and W. Budts Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension Eur. Heart J., September 2, 2004; 25(18): 1651 - 1656. [Abstract] [Full Text] [PDF]

				O. Sitbon, D. B. Badesch, R. N. Channick, A. Frost, I. M. Robbins, G. Simonneau, V. F. Tapson, and L. J. Rubin Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension: A 1-Year Follow-up Study Chest, July 1, 2003; 124(1): 247 - 254. [Abstract] [Full Text] [PDF]

				A. Widlitz and R.J. Barst Pulmonary arterial hypertension in children Eur. Respir. J., January 1, 2003; 21(1): 155 - 176. [Abstract] [Full Text] [PDF]

				H. Suhara, Y. Sawa, N. Fukushima, K. Kagisaki, C. Yokoyama, T. Tanabe, S. Ohtake, and H. Matsuda Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats J. Thorac. Cardiovasc. Surg., May 1, 2002; 123(5): 855 - 861. [Abstract] [Full Text] [PDF]

				W Budts, N Van Pelt, H Gillyns, M Gewillig, F Van de Werf, and S Janssens Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome Heart, November 1, 2001; 86(5): 553 - 558. [Abstract] [Full Text] [PDF]

				R J BARST Role of atrial septostomy in the treatment of pulmonary vascular disease Thorax, February 1, 2000; 55(2): 95 - 96. [Full Text]

				R. J. Barst Do No Harm Chest, November 1, 1999; 116(5): 1147 - 1148. [Full Text] [PDF]

				D. Wax, R. Garofano, and R. J. Barst Effects of Long-term Infusion of Prostacyclin on Exercise Performance in Patients With Primary Pulmonary Hypertension Chest, October 1, 1999; 116(4): 914 - 920. [Abstract] [Full Text] [PDF]

				E. B. Rosenzweig, D. Kerstein, and R. J Barst Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects Circulation, April 13, 1999; 99(14): 1858 - 1865. [Abstract] [Full Text] [PDF]

				R. J. Barst, G. Maislin, and A. P. Fishman Vasodilator Therapy for Primary Pulmonary Hypertension in Children Circulation, March 9, 1999; 99(9): 1197 - 1208. [Abstract] [Full Text] [PDF]

				W. M. Novick, A. T. Gurbuz, D. C. Watson, V. V. Lazorishinets, A. N. Perepeka, I. Malcic, B. Marinovic, B. S. Alpert, and T. G. DiSessa Double patch closure of ventricular septal defect with increased pulmonary vascular resistance Ann. Thorac. Surg., November 1, 1998; 66(5): 1533 - 1538. [Abstract] [Full Text] [PDF]

				V. V. McLaughlin, D. E. Genthner, M. M. Panella, and S. Rich Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension N. Engl. J. Med., January 29, 1998; 338(5): 273 - 277. [Abstract] [Full Text] [PDF]

				L. J. Rubin Primary Pulmonary Hypertension N. Engl. J. Med., January 9, 1997; 336(2): 111 - 117. [Full Text] [PDF]

				R. J. Barst, L. J. Rubin, W. A. Long, M. D. McGoon, S. Rich, D. B. Badesch, B. M. Groves, V. F. Tapson, R. C. Bourge, B. H. Brundage, et al. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension N. Engl. J. Med., February 1, 1996; 334(5): 296 - 301. [Abstract] [Full Text] [PDF]

				N. D. Bridges, G. B. Mallory Jr, C. B. Huddleston, C. E. Canter, S. C. Sweet, and T. L. Spray Lung Transplantation in Children and Young Adults With Cardiovascular Disease Ann. Thorac. Surg., April 1, 1995; 59(4): 813 - 820. [Abstract] [Full Text]

				D. Kerstein, P. S. Levy, D. T. Hsu, A. J. Hordof, W. M. Gersony, and R. J. Barst Blade Balloon Atrial Septostomy in Patients With Severe Primary Pulmonary Hypertension Circulation, April 1, 1995; 91(7): 2028 - 2035. [Abstract] [Full Text]